Search results
Showing 811 to 825 of 1426 results for primary care
Evidence-based recommendations on avalglucosidase alfa (Nexviadyme) for Pompe disease.
Evidence-based recommendations on Parafricta Bootees and Undergarments to reduce skin breakdown in people with or at risk of pressure ulcers.
NICE has developed a medtech innovation briefing (MIB) on d-Nav insulin management app for type 2 diabetes .
Evidence-based recommendations on AposHealth for knee osteoarthritis.
Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine (TA535)
Evidence-based recommendations on lenvatinib (Lenvima) and sorafenib (Nexavar) for progressive, locally advanced or metastatic differentiated thyroid cancer in adults who have had radioactive iodine.
Evidence-based recommendations on daratumumab (Darzalex) for newly diagnosed systemic amyloid light-chain amyloidosis in adults.
Digital therapy for chronic tic disorders and Tourette syndrome: early value assessment (HTG748)
Early value assessment (EVA) guidance on digital therapy for chronic tic disorders and Tourette syndrome.
Alcohol interventions in secondary and further education (NG135)
This guideline covers interventions in secondary and further education to prevent and reduce alcohol use among children and young people aged 11 up to and including 18. It also covers people aged 11 to 25 with special educational needs or disabilities in full-time education. It will also be relevant to children aged 11 in year 6 of primary school.
Infliximab and adalimumab for the treatment of Crohn's disease (TA187)
Evidence-based recommendations on infliximab (Remicade) and adalimumab (Humira) for treating severe active Crohn's disease in adults.
Dupilumab for treating moderate to severe prurigo nodularis (TA955)
Evidence-based recommendations on dupilumab (Dupixent) for treating moderate to severe prurigo nodularis in adults when systemic treatment is suitable.
Asfotase alfa for treating paediatric-onset hypophosphatasia (HST23)
Evidence-based recommendations on asfotase alfa (Strensiq) for treating paediatric-onset hypophosphatasia in babies, children, young people and adults.
Browse the complete list of all our published health and social care guidance, including guidelines, NICE advice and quality standards
This guidance has been updated and replaced by NICE healthtech guidance 690.
mental illness with substance misuse and what are the physical health, social care, housing or other support needs of people with this...
Evidence-based recommendations on ganaxolone (Ztalmy) for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over.